February 12, 2020 / 11:54 AM / 13 days ago

BRIEF-Veru Q1 Loss Per Share $0.05

Veru Inc:

* VERU CONTINUES STRONG POSITIVE SALES MOMENTUM IN FISCAL 2020 FIRST QUARTER; NET REVENUES INCREASE 66%, GROSS PROFIT UP 57%

* Q1 LOSS PER SHARE $0.05

* Q1 EARNINGS PER SHARE ESTIMATE $-0.02 — REFINITIV IBES DATA

* Q1 REVENUE $10.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $8.8 MILLION

* COMPLETION OF VERU-111 PHASE 1B CLINICAL TRIAL AND INITIATION OF PHASE 2 PROSTATE CANCER CLINICAL TRIAL IN Q2 FY 2020

* COMPANY WILL SUBMIT AN NDA FOR TADFIN WHICH IS EXPECTED IN SECOND HALF OF 2020

* VERU SEES ZUCLOMIPHENE ENTERING PIVOTAL PHASE 3 CLINICAL TRIAL FOR TREATING HOT FLASHES IN MEN WITH PROSTATE CANCER ON ADT AFTER MEETING WITH FDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below